等待开盘 02-06 09:30:00 美东时间
-0.610
-1.28%
今日重点评级关注:HC Wainwright & Co.:维持Rezolve AI"买入"评级,目标价从10美元升至12美元;HC Wainwright & Co.:维持Largo"买入"评级,目标价从2.9美元升至3.1美元
01-15 16:10
今日重点评级关注:HC Wainwright & Co.:维持NioCorp Developments"买入"评级,目标价从9.5美元升至11.25美元;摩根士丹利:维持Chewy"超配"评级,目标价从48美元升至51美元
01-14 11:25
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22
今日重点评级关注:Needham:维持Vaxcyte"买入"评级,目标价从90美元升至110美元;Citizens: 维持LGI Homes"跑赢大市"评级,目标价从85美元升至95美元
01-08 18:33
JP Morgan analyst Jimmy Bhullar maintains Ryan Specialty Hldgs (NYSE:RYAN) with a Underweight and lowers the price target from $63 to $56.
01-07 23:59
Last week's big large-cap laggards were led by Brown-Forman, Carvana, and Stellantis, with Starbucks, Samsara, Ryan Specialty, PepsiCo, Texas Pacific Land, On Holding, and General Mills also sliding on analyst actions, labor unrest, and regulatory concerns.
2025-12-28 20:31
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
Mizuho analyst Yaron Kinar initiates coverage on Ryan Specialty Hldgs (NYSE:RYAN) with a Neutral rating and announces Price Target of $61.
2025-12-16 21:21
今日重点评级关注:RBC Capital:上调Neumora Therapeutics评级至"跑赢大市",目标价从4美元升至7美元;HC Wainwright & Co.:维持ProMIS Neurosciences"买入"评级,目标价从4美元升至18美元
2025-12-02 09:50
TD Cowen analyst Andrew Kilgerman maintains Ryan Specialty Hldgs (NYSE:RYAN) with a Buy and lowers the price target from $89 to $76.
2025-11-27 00:21